Skip to main content
. 2019 Sep 3;10:2029. doi: 10.3389/fmicb.2019.02029

FIGURE 4.

FIGURE 4

Time-kill curves for polymyxin B (PMB) and ceftazidime/avibactam (CZA) monotherapy and combination therapy against polymyxin B-susceptible K. pneumoniae ATCC 700603, and polymyxin B-heteroresistant K. pneumoniae (B1, D1, and D4). (A,E,I,M) PMB (0.5, 1, and 2 mg/L) as monotherapy; (B,F,J,N) PMB (0.5, 1 and 2 mg/L) in combination with CZA (0.25 × MIC); (C,G,K,O) PMB (0.5, 1 and 2 mg/L) in combination with CZA (0.5 × MIC); (D,H,L,P) PMB (0.5, 1 and 2 mg/L) in combination with CZA (1 × MIC). The limit of quantification is indicated by black dashed horizontal lines.